China Approves Obesity Drug for Severe Fatty Liver Disease

Дата публикации: 14-09-2026 00:00:00

The approval follows increased competition among pharmaceutical companies pushing to attain weight-loss medication approval to treat a wider range of illnesses.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	China Pushes for Homes to Be Completed Before They’re Sold	0	7.19	02-09-2026
2	China Tells E-Commerce Apps to Stop Selling Loans	0	13	21-09-2026
3	GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch	0	9.8	11-05-2026
4	Weighty matters	0	18.33	30-08-2026
5	Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B	0	12.98	30-03-2026
6	Eating Less Reduced Breast Tumors in Mice, Chinese Study Finds	0	7.12	01-09-2026
7	Solar, Auto, nun Pharma: China greift die nächste Branche an	0	12.94	28-08-2026
8	Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis	0	8.52	26-02-2026
9	China Moves to Address Self-Driving Cars in National Law	0	9.53	07-09-2026
10	The Information: Китай рассматривает допуск ByteDance и Alibaba к новым чипам NVIDIA	0	8.92	28-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.46. Источник: www.sixthtone.com.